Dr. Bruce Sands discusses his presentation of the new pivotal Phase 3 data at the American College of Gastroenterology (ACG) Annual Scientific Meeting showing that a single IV dose of STELARA® (ustekinumab) – the first and only biologic targeting interleukin (IL)-12 and -23 cytokines – induced clinical remission in a greater percentage of adult patients with moderate-to-severe ulcerative colitis (UC), compared to those receiving placebo. Gastroenterology, Remission, American Colleges, Ulcerative Colitis, Placebo, Ulcers, Percentage, Sands, Medical Professionals
Save
healthprofessionalradio.com.au

Pin on Advertisement with HPR

Nov 20, 2018 - Dr. Bruce Sands discusses STELARA (ustekinumab) – the first and only biologic targeting interleukin (IL)-12 and -23 cytokines

Comments

Comments are turned off for this Pin